About one in four drugs made it from being a new molecular entity (NME) in 2013 to approval in five years, according to a report on the pipeline progress for eight large biotechs analyzed by SVB Leerink analyst Geoffrey Porges. Externally acquired NMEs had a higher conversion rate, with 32% making it to market, compared to 21% of internally developed drugs.
Looking to join the 12 drug companies that have gone public this year, Cortexyme Inc., Milestone Pharmaceuticals Inc., Applied Therapeutics Inc. and Nextcure Inc. all filed preliminary prospectuses with the SEC on Friday.
Last week, the FDA approved Dovato, the first two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV. The drug combines dolutegravir, an integrase strand transfer inhibitor, and lamivudine, a nucleoside reverse transcriptase inhibitor (nuc).
Last week, the FDA approved Dovato, the first two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV. The drug combines dolutegravir, an integrase strand transfer inhibitor, and lamivudine, a nucleoside reverse transcriptase inhibitor (nuc).
United Therapeutics Corp. is discontinuing development of esuberaprost (beraprost 314d), an oral prostacyclin analogue, after its phase III Beat study in patients with pulmonary arterial hypertension (PAH) failed to meet the primary endpoint.
Initial data from the highest dose of the phase I/II Alta trial testing Sangamo Therapeutics Inc. and Pfizer Inc.'s SB-525 hemophilia A gene therapy look promising.
Initial data from the highest dose of the phase I/II Alta trial testing Sangamo Therapeutics Inc. and Pfizer Inc.'s SB-525 hemophilia A gene therapy look promising.
Quarter after quarter, analysts have been pestering management on Biogen Inc.'s conference calls about whether there would be an interim analysis for the phase III program testing its Alzheimer's disease drug aducanumab.
Quarter after quarter, analysts have been pestering management on Biogen Inc.'s conference calls about whether there would be an interim analysis for the phase III program testing its Alzheimer's disease drug aducanumab.
